AstraZeneca
RA setbacks for AstraZeneca and Lilly
December 14, 2012Research and Development, Sales and Marketing AstraZeneca, Humira, RA, lilly
AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …
Forxiga approved in European Union
November 15, 2012Sales and Marketing AstraZeneca, BMS, Forxiga, diabetes
AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga has been approved in Europe – a major filip for …
Germany dismisses Seroquel XR
November 14, 2012Sales and Marketing AstraZeneca, FDA, Germany, Seroquel XR
AstraZeneca has received another dent in its international attempts to keep the money-spinning antipsychotic Seroquel going in a new form. …
AstraZeneca signs genome deal
November 13, 2012Research and Development, Sales and Marketing AstraZeneca, Foundation, SMIP
AstraZeneca has signed a genomic profiling agreement with US molecular information company Foundation Medicine. The collaboration will use its FoundationOne …
MRC gives £7 million to new projects
November 6, 2012Sales and Marketing AstraZeneca, MRC, academics
The Medical Research Council (MRC) has handed out £7 million in funding for 15 research projects which will use a …
Sharp fall for AstraZeneca
October 26, 2012Sales and Marketing AstraZeneca, Brennan, Q3, Soriot
AstraZeneca saw its third quarter revenue and pre-tax profit both fall 15%, to $6.7 billion and $2 billion, respectively. The …
AstraZeneca and Ironwood announce $150 million China pact
October 25, 2012Research and Development, Sales and Marketing AstraZeneca, China, IBS, Ironwood
AstraZeneca has signed a deal with Ironwood to co-develop and co-market Ironwood’s irritable bowel syndrome treatment in China. In August …
AZ licences renal disease compound
October 9, 2012Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3
AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …
Pharma creates non-profit R&D organisation
September 21, 2012Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma
Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …
Asia-Pacific – pharma’s new centre of gravity?
September 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Asia-Pacific, AstraZeneca
A high-growth region for the pharmaceutical industry, Asia-Pacific incorporates a vast geography with a $20 trillion economy, and is home …
AstraZeneca signs MIT/Harvard research deal
September 17, 2012Business Services, Research and Development, Sales and Marketing AstraZeneca, Deals, Havard, MIT
AstraZeneca has signed a two-year collaboration with an academic institution – affiliated to the illustrious universities MIT and Harvard – …
MedImmune signs China deal
September 11, 2012Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China, MedImmune, WuXi, emerging markets, rheumatoid arthritis
MedImmune has sealed a joint venture with Shanghai-based WuXi AppTec to develop a novel biologic for autoimmune and inflammatory diseases …
AstraZeneca poaches Soirot from Roche to be new chief executive
August 28, 2012Sales and Marketing AstraZeneca, Soirot
AstraZeneca has poached Roche’s head of pharma, Pascal Soriot, to be its new chief executive. He joins on 1 October. …
Pfizer pays $250m for OTC Nexium rights
August 14, 2012Sales and Marketing AstraZeneca, EMA, FDA, Nexium, OTC, Pfizer
Pfizer will pay $250 million to AstraZeneca in order to gain the rights to sell an over-the-counter form of the …
AstraZeneca and BTG sepsis drug fails
August 8, 2012Research and Development, Sales and Marketing AZD977, AstraZeneca, BTG, CytoFab, sepsis
AstraZeneca’s pipeline has suffered another blow with the troubled company halting development of an investigational sepsis drug following poor Phase …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
